ClinicalTrials.gg
CompletedNCT02678416Updated Feb 5, 2020Results posted

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

A Phase 4 interventional study of IV Acetaminophen (Treatment A) and Oral Acetaminophen (Treatment B) in Pain, sponsored by Mallinckrodt. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Mallinckrodt · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
80th of 137
79 · median 95
Started
2015
with 11 others
Phase 4
67 of 137
5 open now
Registered
89th of 137
by date
Lead sponsor
6 of 137
Mallinckrodt

Among the 137 studies testing acetaminophen in Pain, this one is the 80th largest by enrollment, is one of 12 that started in 2015, is one of 67 in phase 4, and was the 89th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate two experimental pain models to see if they would be useful for comparing different products for reduction in pain intensity.

The models evaluated were the ultraviolet-B (UVB) burn and intradermal capsaicin experimental pain models. Medications compared were a single dose each, of intravenous (IV) acetaminophen, oral acetaminophen, placebo, and IV morphine.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • comparison
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a health status of "healthy" assessed by the investigator and defined as no deviation from normal medical history, physical examination, vital signs, and clinical laboratory determinations.
  2. Must be male, Caucasian, between 18 and 55 years of age (inclusive) at the time of the screening.
  3. Must have a (BMI) ≥ 19.0 and ≤ 30.0 kg/m2 with a minimum weight of 110 pounds (50 kg) at screening.

Exclusion criteria

Exclusion Criteria

  1. A positive test result for (HIV), (surface antigen), or virus antibody at Screening.
  2. A history of any drug allergy, , or intolerance to acetaminophen, morphine, or capsaicin or to any of the in the IV or oral formulations used.
  3. A positive test result for drugs of abuse, alcohol, or cotinine.
  4. Fitzpatrick Skin Type V or VI (based on a Skin Type score of greater than 30.
  5. A history of conditions which might be specifically or require caution to be used during the administration of any drug in the study.
  6. Any other medical, psychiatric and/or social reason for exclusion as determined by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    IV Acetaminophen

    All participants receive IV acetaminophen as one of 4 interventions in random sequence

    Drug: IV Acetaminophen (Treatment A) · Drug: Placebo (Treatment C)

  • Experimental
    Oral Acetaminophen

    All participants receive oral acetaminophen as one of 4 interventions in random sequence

    Drug: Oral Acetaminophen (Treatment B) · Drug: Placebo (Treatment C)

  • Experimental
    Placebo

    All participants receive placebo as one of 4 interventions in random sequence

    Drug: Placebo (Treatment C)

  • Experimental
    Morphine

    All participants receive morphine as one of 4 interventions in random sequence

    Drug: Placebo (Treatment C) · Other: Morphine (Treatment D)

Interventions

  • Acetaminophen administered by intravenous (IV) infusion

    Also known as: OFIRMEV

  • Acetaminophen administered by oral tablets

    Also known as: Acetaminophen tablets

  • DrugPlacebo (Treatment C)

    Placebo administered by IV infusion or oral tablets

    Also known as: IV Placebo, Placebo tablets

  • OtherMorphine (Treatment D)

    Morphine administered by IV infusion

    Also known as: IV Morphine

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model

    The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).

    Time frame: within 6 hours

Secondary outcomes

  1. Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area

    Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6

    Time frame: within 6 hours

07

Results

Posted Dec 20, 2019

Participant flow

A total of 79 participants were enrolled in the study. 12 participants in Part 1 and 66 participants in Part 2 were randomized to sequence, and received at least one dose of the study treatment.

Part 1
Participant flow — Part 1
MilestonePart 1
Started12
Safety population12
Modified intent to treat (mitt)12
Per protocol population8
Completed11
Not completed1
Withdrew: Withdrawal by subject1
Part 2
Participant flow — Part 2
MilestonePart 1
Started67
Treated (safety population)66
Modified intent to treat population66
Pharmacokinetic population65
Per protocol population64
Completed64
Not completed3
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPart 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model

The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).

Time frame:
within 6 hours
Reported as:
Mean · score on a scale
Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model
score on a scaleIV AcetaminophenOral AcetaminophenPlaceboMorphine
Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model0.73 ± 1.104-0.64 ± 1.804-0.36 ± 1.5670.36 ± 1.206
SecondaryPart 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area

Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6

Time frame:
within 6 hours
Reported as:
Mean · scores on a scale
Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area
scores on a scalePart 2: IV AcetaminophenPart 2: Oral AcetaminophenPart 2: PlaceboPart 2: IV Morphine
Baseline5.4 ± 1.305.5 ± 1.405.5 ± 1.325.6 ± 1.40
0.25 Hours5.2 ± 1.395.3 ± 1.485.5 ± 1.284.9 ± 1.56
0.5 Hours5.0 ± 1.345.1 ± 1.365.3 ± 1.284.7 ± 1.50
0.75 Hours5.0 ± 1.375.1 ± 1.305.4 ± 1.264.7 ± 1.62
1 Hour5.0 ± 1.444.9 ± 1.235.2 ± 1.344.6 ± 1.55
2 Hours5.3 ± 1.135.1 ± 1.265.6 ± 1.285.1 ± 1.50
3 Hours5.4 ± 1.305.2 ± 1.445.5 ± 1.235.0 ± 1.67
4 Hours5.5 ± 1.175.4 ± 1.405.5 ± 1.305.2 ± 1.42
6 Hours5.6 ± 1.325.5 ± 1.305.5 ± 1.345.4 ± 1.45

Adverse events

Collected over From first dose up to Day 46. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: IV Acetaminophen0/12 (0%)0/12 (0%)2/12 (16.7%)
Part 1: Oral Acetaminophen0/12 (0%)0/12 (0%)2/12 (16.7%)
Part 1: Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
Part 1: Morphine0/12 (0%)0/12 (0%)8/12 (66.7%)
Part 2: IV Acetaminophen0/64 (0%)0/64 (0%)10/64 (15.6%)
Part 2: Oral Acetaminophen0/65 (0%)0/65 (0%)12/65 (18.5%)
Part 2: Placebo0/65 (0%)0/65 (0%)14/65 (21.5%)
Part 2: Morphine0/64 (0%)0/64 (0%)38/66 (57.6%)
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPart 1: IV AcetaminophenPart 1: Oral AcetaminophenPart 1: PlaceboPart 1: MorphinePart 2: IV AcetaminophenPart 2: Oral AcetaminophenPart 2: PlaceboPart 2: Morphine
DizzinessNervous system disorders1/120/120/124/121/642/651/6520/66
SomnolenceNervous system disorders0/120/120/124/120/640/651/6510/66
SyncopeNervous system disorders0/120/120/123/120/640/650/651/66
NauseaGastrointestinal disorders0/120/120/121/120/641/651/659/66
VomitingGastrointestinal disorders0/120/120/121/120/640/651/655/66
HeadacheNervous system disorders1/120/120/120/121/644/653/654/66
ParaesthesiaNervous system disorders0/120/120/121/121/641/652/655/66
MyalgiaMusculoskeletal and connective tissue disorders1/121/121/120/120/640/650/650/66
Axillary PainGeneral disorders0/120/121/120/120/640/650/650/66
Injection Site ReactionGeneral disorders0/120/121/120/120/640/650/650/66

Baseline characteristics

Safety Population, defined as participants enrolled in the study that received any quantity of study drugs. All new participants were enrolled in Part 2.

Age, Continuous
Age, Continuous(years)Part 1Part 2Total
Mean28.9 (19 to 49)26.5 (18 to 52)26.9 (18.2 to 51.5)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female000
Male126678
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1Part 2Total
Race, White — Not Hispanic or Latino126072
Race, White — Hispanic or Latino066
Region of Enrollment
Region of Enrollment(Participants)Part 1Part 2Total
United States126678
08

Study locations

1 site
  • Pharmaceuticals Research Associates, Inc. (PRA)
    Salt Lake City, Utah 84106, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jun 2016, 6 months.

Results were first posted in Dec 2019, 3 years 6 months after primary completion.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 9, 2016
StartActual
Dec 7, 2015
Primary completionActual
Jun 13, 2016
CompletionActual
Jun 13, 2016
Results first posted
Dec 20, 2019
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02678416
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Feb 9, 2016
Start date
Dec 7, 2015
Primary completion
Jun 13, 2016
Completion
Jun 13, 2016
Results posted
Dec 20, 2019
Last update
Feb 5, 2020

Study contacts

Global Clinical Leader
study director · Mallinckrodt

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion